Tekmira Pharmaceuticals Corporation is a publicly-traded biopharmaceutical company located in Vancouver, Canada. Recognized as a world leader in RNA interference (RNAi) delivery technology, we are focused on advancing novel RNAi-based product candidates.

Research Grants 105 show all


$72.7K
2011

$87.4K
2012

$39.6K
2013

$24.4K
2014

$3.5K
2015

Patents 225show all

  • 85
    A61K - Preparations for medical, dental, or toilet purposes
  • 38
    C12N - Microorganisms or enzymes
  • 10
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 8
    C12Y - Enzymes
  • 5
    A01K - Animal husbandry
  • 5
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 5
    Y02A - Technologies for adaptation to climate change
  • 4
    C07C - Acyclic or carbocyclic compounds
  • 2
    C07D - Heterocyclic compounds
  • 2
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium

Clinical Trials 3show all

2Phase 1/Phase 21Phase 1

SEC Filings show all


177
8-K

18
10-Q

7
10-K

2
D

Contact Information

Burnaby
Canada

SEC Form D Funding Events

DateOfferedSoldType
2009-03-23Indefinite$0Option to Acquire
2008-10-01Unknown Unknown Other (Paper Filing)

Key Executives

  • Dr. Arthur M Bruskin
    Director
  • Dr. Michael J Abrams
    Director
  • Dr. Ian Maclachlan
    Executive Officer
  • Michael K Forrest
    Director
  • Dr. Mark J Murray
    Executive Officer
  • Donald Jewell
    Director
  • Gary E Frashier
    Director
  • James W Hudson
    Director
  • R. Ian Lennox
    Director
  • Ian Mortimer
    Executive Officer